GI CONNECT Update from ESMO 2022 Ep 1: lower GI cancer highlights

Episode 1 September 20, 2022 00:23:43
GI CONNECT Update from ESMO 2022 Ep 1: lower GI cancer highlights
COR2ED Medical Education
GI CONNECT Update from ESMO 2022 Ep 1: lower GI cancer highlights

Sep 20 2022 | 00:23:43

/

Show Notes

COR2ED Medical Education: In the first episode of this GI CONNECT podcast covering the lower gastrointestinal (GI) cancer highlights from ESMO 2022, Dr Jenny Seligmann, Medical Oncologist from the University of Leeds in the UK and Dr Dominik Modest, Medical Oncologist from the Charité Universitaetsmedizin, Berlin, Germany discuss a number of key oral presentations from ESMO 2022 and potential implications for clinical practice. 

They start their discussion with the  NICHE-2 which looked at neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer. Discussion then moves to the HIPECT4 trial which explored adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer and challenges previous perceptions of HIPEC in colorectal cancer patients. The FRESCO-2 trial is reviewed which evaluated the efficacy and safety of fruquintinib in patients with refractory metastatic CRC with results potentially supporting a new option for these patients. The experts then review two trials in patients with KRASG12C mutant CRC, the KRYSTAL-1 which used adagrasib with or without cetuximab in these patients and the CodeBreaK101 study which used sotorasib in combination with panitumumab.  They discuss their opinions on the results from these studies and the implications for clinical practice.

Other Episodes

Episode 2

October 21, 2021 00:24:56
Episode Cover

Choosing the Best Treatment Regimen in Multiple Myeloma: Episode 2 – the Relapsed/Refractory Setting

In this medical education podcast series, myeloma experts Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford University Hospitals in London,...

Listen

Episode 2

October 03, 2021 00:16:30
Episode Cover

ASBMR 2021 Rare Bone Disease Highlights from Day Two

We have partnered with international experts to provide rare bone diseases highlights from ASBMR 2021. This is the second in a series of four...

Listen

Episode 3

February 10, 2022 00:26:43
Episode Cover

PARP inhibitors in prostate cancer: Management of adverse events and the importance of communication with patients

COR2ED Medical Education: Dr Jason Alcorn, nurse consultant for Uro-Oncology & Andrology at the Mid Yorkshire Hospitals NHS Trust, United Kingdom and Dr Alicia...

Listen